Agilent Technologies

558 articles with Agilent Technologies

• Agilent Laboratory Achieves Green Lab Certification

  6/21/2022

  Agilent Technologies Inc. (NYSE: A) today announced that the company’s customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification , the gold standard in laboratory sustainability best practices.

• Agilent Showcases ‘Consistent, Greener, Smarter’ Approach at Analytica 2022

  6/16/2022

  Agilent Technologies Inc. (NYSE: A) today announced that it will showcase its latest workflows and solutions at Analytica 2022, being held 21 to 24 June 2022 in Munich, Germany.

• Agilent Wins Multiple 2022 Scientists' Choice Awards at ASMS

  6/15/2022

  Agilent Technologies Inc. (NYSE: A) announced that it has received three 2022 Scientists’ Choice Awards including Best New Spectroscopy Product of 2021.

• Agilent Announces New Revolutionary Quadrupole Mass Spectrometers at ASMS 2022

  6/6/2022

  Agilent Technologies Inc. (NYSE: A) today announced new LC/MS and GC/MS quadrupole mass spectrometers which will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being held June 5 - 9, 2022 in Minneapolis, Minnesota.

• Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research

  6/6/2022

  Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation.

• Agilent to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

  6/1/2022

  Agilent Technologies Inc. announced the company will participate in the Goldman Sachs 43rd Annual Healthcare Conference on Wednesday, June 15, in Rancho Palos Verdes, California.

• Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union

  6/1/2022

  Agilent Technologies Inc. (NYSE: A) today announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR regulation.

• Agilent Announces Collaboration with APC on Real-Time Process Monitoring

  5/27/2022

  Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd. , in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC).

• Agilent Reports Second-Quarter Fiscal Year 2022 Financial Results

  5/24/2022

  Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.61 billion for the second quarter ended April 30, 2022, an increase of 5% compared to the second quarter of 2021 and up 7% on a core(1) basis.

• Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer

  5/10/2022

  Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in identifying cervical cancer patients for whom treatment with KEYTRUDA® (pembrolizumab) may be appropriate.

• Agilent to Announce Second-Quarter Fiscal Year 2022 Financial Results May 24

  4/26/2022

  Agilent Technologies Inc. (NYSE: A) today announced that it will release financial results for the second quarter of fiscal year 2022 after the stock market closes on Tuesday, May 24.

• Agilent Highlights Genomics and Cell Analysis Solutions for Cancer Research at AACR 2022

  4/8/2022

  Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting , being held April 8 - 13, 2022 in New Orleans, Louisiana.

• Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC)

  4/5/2022

  Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed with muscle-invasive urothelial carcinoma (MIUC).

• Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma

  4/5/2022

  Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma.

• Agilent Joins AMBIC to Advance Biomanufacturing

  4/4/2022

  Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC).

• Agilent Announces the 2022 Darlene Solomon Award Presented to Grenoble Alpes University Hospital Scientist Dr. Federica Fiorini

  3/10/2022

  Agilent Technologies Inc. announced that the recipient of the 2022 Darlene Solomon Award is Federica Fiorini, Ph.D., a research associate studying metabolomics at the Institute of Biology and Pathology at the Grenoble Alpes University Hospital in France.

• Singular Genomics Partners with Agilent to Enable the SureSelect Target Enrichment Reagents for the G4 Sequencing Platform

  2/28/2022

  Singular Genomics Systems, Inc. today announced a partnership with Agilent Technologies ( www.agilent.com ) to validate its NGS Target Enrichment Products, highly sensitive target enrichment panels with either custom or catalog kits, with the G4 sequencing platform.

• Agilent to Participate at Cowen and Barclays Health Care Conferences

  2/24/2022

  Agilent Technologies Inc. announced that Bob McMahon, senior vice president and chief financial officer, will participate in Q&A sessions at the Cowen 42nd Annual Health Care Conference and the Barclays Global Health Care Conference.

• Agilent and University of Vermont Announce the Agilent Laboratory for Chemical Analysis (ALCA)

  2/24/2022

  Agilent Technologies Inc. and the University of Vermont announced the establishment of the Agilent Laboratory for Chemical Analysis.

• Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening

  2/23/2022

  Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a proof-of-concept FTIR-based saliva COVID-19 testing workflow using the Agilent Cary 630 FTIR Spectrometer.